Table 1.
Baseline Characteristics of Patients with Chronic Hepatitis C According to Treatment Response
| |
Median (25–75 percentiles) |
|
||
|---|---|---|---|---|
| Patient characteristics | Non-SVR (n=20) | SVR (n=26) | Total patient group (n=46) | P value |
| Age (years) | 50.5 (39–59) | 35 (28–40) | 39.5 (30–52) | 0.0012 |
| Sex (n, %) | 0.391 | |||
| Male | 6 (30%) | 11 (42.3%) | 17 (37%) | |
| Female | 14 (45%) | 15 (57.7%) | 29 (63%) | |
| Liver biopsy (ISHAK score) | ||||
| Fibrosis (n, %) | 0.010 | |||
| Stage 1–3 | 11 (55%) | 23 (88.5%) | 34 (73.9%) | |
| Stage 4–6 | 9 (45%) | 3 (11.5%) | 12 (26.1%) | |
| Histology activity index (HAI, n, %) | 0.364 | |||
| HAI 0–6 | 6 (30%) | 7 (26.9%) | 13 (28.3%) | |
| HAI 7–12 | 11 (55%) | 18 (69.2%) | 29 (63%) | |
| HAI 13–18 | 3 (15%) | 1 (3–8%) | 4 (8.7%) | |
| HCV RNA (IU/mL) before treatment | 727,084 (280,140–1,700,000) | 266,045 (93,900–694,000) | 354,132 (165,000–1,243,560) | 0.036 |
| Body mass index | 23.9 (22–25.5) | 23.7 (21–24.9) | 23.7 (21.9–25) | 0.527 |
HCV, hepatitis C virus; SVR, sustained viral response.